Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
ASBP stock price ended at $1.13 on 水曜日, after rising 41.25%
On the latest trading day Mar 25, 2026, the stock price of ASBP rose by 41.25%, climbing from $0.83 to $1.13. During the session, the stock saw a volatility of 55.42%, with prices oscillating between a daily low of $0.83 and a high of $1.29. Notably, trading volume dropped by 7.1M shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 7.4M shares were traded, equating to a market value of approximately $5.6M.